Genmab A/S (NASDAQ:GMAB) Given Consensus Rating of “Hold” by Analysts

Genmab A/S (NASDAQ:GMAB) has been assigned an average rating of “Hold” from the thirteen ratings firms that are covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $49.50.

A number of analysts recently issued reports on GMAB shares. BTIG Research boosted their price objective on Genmab A/S from $46.00 to $47.00 and gave the company a “buy” rating in a research note on Thursday. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a research note on Thursday. Morgan Stanley restated an “underweight” rating on shares of Genmab A/S in a research note on Tuesday, March 26th. Finally, Truist Financial upped their target price on Genmab A/S from $50.00 to $53.00 and gave the stock a “buy” rating in a research note on Tuesday, June 4th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of GMAB. HighTower Advisors LLC increased its holdings in Genmab A/S by 30.7% in the 3rd quarter. HighTower Advisors LLC now owns 9,009 shares of the company’s stock valued at $322,000 after purchasing an additional 2,114 shares during the last quarter. Citigroup Inc. increased its holdings in Genmab A/S by 148.2% in the 3rd quarter. Citigroup Inc. now owns 21,545 shares of the company’s stock valued at $760,000 after purchasing an additional 12,863 shares during the last quarter. FMR LLC increased its holdings in Genmab A/S by 6.3% in the 3rd quarter. FMR LLC now owns 422,437 shares of the company’s stock valued at $14,899,000 after purchasing an additional 24,936 shares during the last quarter. Mariner LLC increased its holdings in Genmab A/S by 183.4% in the 3rd quarter. Mariner LLC now owns 49,018 shares of the company’s stock valued at $1,729,000 after purchasing an additional 31,720 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in Genmab A/S by 83.3% in the 3rd quarter. Northern Trust Corp now owns 559,044 shares of the company’s stock valued at $19,717,000 after purchasing an additional 254,042 shares during the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Trading Down 0.4 %

Shares of GMAB stock opened at $25.58 on Friday. The stock has a market cap of $16.92 billion, a price-to-earnings ratio of 21.32, a PEG ratio of 0.94 and a beta of 0.99. The stock has a 50-day moving average of $28.08 and a 200-day moving average of $29.18. Genmab A/S has a 1-year low of $25.38 and a 1-year high of $42.72.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, May 2nd. The company reported $0.16 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.16. Genmab A/S had a return on equity of 18.90% and a net margin of 30.74%. The business had revenue of $603.30 million for the quarter, compared to analyst estimates of $594.23 million. Sell-side analysts forecast that Genmab A/S will post 1.11 earnings per share for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.